These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28441149)

  • 1. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
    Dupéré-Richer D; Licht JD
    Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma.
    Rastgoo N; Abdi J; Hou J; Chang H
    J Hematol Oncol; 2017 Jun; 10(1):121. PubMed ID: 28623912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
    Terui Y
    Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Chromatin Remodeling for Cancer Therapy.
    Kaur J; Daoud A; Eblen ST
    Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
    Garcia-Gomez A; Li T; de la Calle-Fabregat C; Rodríguez-Ubreva J; Ciudad L; Català-Moll F; Godoy-Tena G; Martín-Sánchez M; San-Segundo L; Muntión S; Morales X; Ortiz-de-Solórzano C; Oyarzabal J; San José-Enériz E; Esteller M; Agirre X; Prosper F; Garayoa M; Ballestar E
    Nat Commun; 2021 Jan; 12(1):421. PubMed ID: 33462210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
    Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological significance of histone modifiers in multiple myeloma: clinical applications.
    Ohguchi H; Hideshima T; Anderson KC
    Blood Cancer J; 2018 Aug; 8(9):83. PubMed ID: 30190472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.
    Pawlyn C; Kaiser MF; Heuck C; Melchor L; Wardell CP; Murison A; Chavan SS; Johnson DC; Begum DB; Dahir NM; Proszek PZ; Cairns DA; Boyle EM; Jones JR; Cook G; Drayson MT; Owen RG; Gregory WM; Jackson GH; Barlogie B; Davies FE; Walker BA; Morgan GJ
    Clin Cancer Res; 2016 Dec; 22(23):5783-5794. PubMed ID: 27235425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic transitions: towards therapeutic targets.
    Kalebic T
    Expert Opin Ther Targets; 2003 Dec; 7(6):693-9. PubMed ID: 14640906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
    Herranz M; Esteller M
    Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
    Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
    Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic modulators as therapeutic targets in prostate cancer.
    Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
    Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.